ALKS 5461: Phase III started

Alkermes began the double-blind, placebo-controlled, international Phase III FORWARD-5 trial to evaluate once-daily oral ALKS 5461 in about 500 MDD patients. FORWARD-5 will enroll patients who have had an inadequate response to commonly prescribed drugs, including selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs). ...